P53 Over Expression in Bladder Carcinoma
Keywords:urothelial carcinoma, Immunohistochemistry, P53 overexpression, Histopathology, Urology
Objective: The goal of this study was to find out how common p53 overexpression is in bladder urothelial carcinoma.
Material & Methods: This Descriptive, Cross-Sectional Study has been done during April 10th to October 9th, 2018 at the KRL Hospital Islamabad. A total of 74 patients with biopsy-proven urinary bladder carcinoma, ranging in age from 15 to 70 years old and regardless of gender, were included in the study. Patients undergoing radiotherapy, immunotherapy, or who had previously received an immunohistochemistry report were excluded. Following that, the immunohistochemical processing was completed, and the results for p53 expression (positive/negative) were interpreted by the consultant pathologist.
Results: The participants in this study ranged in age from 15 to 70 years old, with a mean age of 47.39 10.26 years. The male to female ratio was 1.6:1 among these 74 patients, with 45 (60.81 percent) being male and 29 (39.19 percent) being female. Overexpression of p53 was found in 31 (41.89 percent) of bladder urothelial carcinoma cases.
Conclusion: This study concluded that the frequency of p53 overexpression in bladder urothelial carcinoma is very high.
Copyright (c) 2022 Annals of PIMS-Shaheed Zulfiqar Ali Bhutto Medical University
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.